Free 24-hour delivery over £75 · Same-day despatchOrder before 2pm - same-day despatch · Free 24-hour delivery over £75
Research use only
All lyophilised (powdered) products and any related items sold by Kovalabs are strictly for scientific research purposes. No dosing guidelines are supplied with any product. We comply with all local regulations governing research-only sales within the United Kingdom. We are not a pharmacy and do not endorse, offer, or provide advice for human or animal consumption. International customers are responsible for checking their own local laws and regulations before purchasing.
You must be 18 or over and purchasing for scientific research only.
By clicking ‘I agree’ you confirm you have read and accepted the terms set out in this disclaimer.
Research use only
· 7 min read
The whole point of CJC-1295 is the part bolted onto the end. Take modified GRF 1-29 - a 29-residue GHRH analogue that, on its own, clears the bloodstream in minutes - and attach a Drug Affinity Complex (DAC): a small chemical handle that latches onto circulating albumin and turns a minutes-long peptide into one with a reported half-life on the order of days. That single conjugation is the difference between "CJC-1295 with DAC" and the no-DAC base, and it is most of why the molecule was designed. Strictly, "CJC-1295" means this DAC-conjugated version. Kovalabs supplies it as a research reagent; everything below describes what published studies investigated, not any human use, benefit or outcome.
| Compound | CJC-1295 with DAC (DAC:GRF) |
|---|---|
| Synonyms | CJC-1295 DAC, DAC:GRF, drug affinity complex GRF |
| Class / mechanism | Long-acting GHRH-receptor (GHRHR) agonist; albumin-binding GHRH(1-29) analogue |
| Molecular formula | C165H269N47O46 |
| Molecular weight | 3647.2 g/mol (average) |
| CAS number | 446262-90-4 |
| PubChem CID | 91971820 |
| Supply status | Research use only - not for human or veterinary use |
CJC-1295 with DAC is the DAC-conjugated form of the modified GRF 1-29 peptide: PubChem CID 91971820, molecular formula C165H269N47O46, average molecular weight 3647.2 g/mol, CAS 446262-90-4. The base peptide is the same tetrasubstituted GHRH(1-29) analogue (D-Ala2, Gln8, Ala15, Leu27) used in the no-DAC version; what the DAC version adds is the Drug Affinity Complex - a lysine linker bearing a maleimidopropionyl group - which accounts for the roughly 279 g/mol of extra mass over the 3367.9 g/mol no-DAC base.
The Drug Affinity Complex is a bioconjugation trick, and a tidy one. The maleimido group on the DAC reacts with a free thiol - specifically Cys34 on serum albumin - forming a covalent bond to the most abundant protein in blood. Albumin circulates for weeks; tethered to it, the peptide is shielded from the rapid enzymatic clearance that disposes of a free GHRH fragment in minutes. The result is a reported circulating persistence measured in days rather than minutes - a pharmacokinetic property attributed to the cited literature, not a usable dosing fact or any statement of effect. The same albumin-bioconjugate strategy was characterised at the receptor level by Jette et al. (Endocrinology, 2005; PMID 15817669), the work that the CJC-1295 series is built on.
| Property | CJC-1295 with DAC (this page) | CJC-1295 No DAC (modified GRF 1-29) |
|---|---|---|
| Molecular formula | C165H269N47O46 | C152H252N44O42 |
| Molecular weight | 3647.2 g/mol | 3367.9 g/mol |
| PubChem CID | 91971820 | 56841945 |
| DAC moiety | Present (lysine + maleimidopropionyl, ~279 mass) | Absent |
| Binds serum albumin | Yes (covalent, via albumin Cys34) | No |
| Reported circulating persistence | On the order of days (study-reported PK) | Minutes (study-reported PK) |
CJC-1295 is grouped here by receptor pharmacology, not by any indication. The base peptide is a GHRH analogue at the growth-hormone-releasing-hormone receptor (GHRHR), a class B secretin-family GPCR on anterior-pituitary somatotrophs - the same receptor as native GHRH and sermorelin. The DAC changes the pharmacokinetics, not the receptor target. One distinction worth stating because the two compounds are so often studied together: CJC-1295 and ipamorelin act on different receptors. CJC-1295 is a GHRH analogue at the GHRHR; ipamorelin is a ghrelin-mimetic growth-hormone secretagogue at the GHS-R1a (ghrelin) receptor. Both sit in the somatotropic axis but engage distinct receptors with distinct ligand classes - a receptor-pharmacology distinction stated as molecular fact, not a combination, protocol or use.
The registered-trial CJC-1295 programme used this DAC-conjugated form. Each item below is stated as study design and the named endpoint only; no result, effect size or benefit is reproduced.
Note these registered studies report safety and pharmacokinetic endpoints by name; this page names them as study endpoints and does not reproduce any tolerability result or translate any figure into a use recommendation. Treat the list as research context, not as findings to expect.
The notes below are general physicochemical and storage information for bench work only. They are not dosing, administration or use instructions, and nothing here describes a preparation for use in humans or animals.
CJC-1295 with DAC is supplied as a white lyophilised powder (often the acetate salt). It is a hydrophilic peptide conjugate and dissolves in aqueous laboratory solvents with gentle swirling rather than vigorous shaking. Standard practice: store the sealed lyophilate desiccated, cold and out of light, frozen for long-term storage; reconstitute in an appropriate aqueous solvent and aliquot to avoid freeze-thaw cycles. See the reconstitution guide. One conjugate-specific note for assay design: the value of the DAC is its reactive maleimido group, which is designed to bind a free thiol (albumin Cys34) - so an experiment relying on the intact conjugate should account for that reactivity. The defining identity check is mass: the DAC form (3647.2 g/mol) and the no-DAC base (3367.9 g/mol) are routinely both called "CJC-1295", so the lot certificate of analysis is what confirms which is in the vial. The base peptide is covered in the CJC-1295 DAC vs No-DAC reference, within the GH-axis research category.
Tier one is solid: the chemistry is settled. The DAC form is a defined molecule (PubChem CID 91971820, C165H269N47O46, CAS 446262-90-4), it has been identified analytically in real preparations, and the albumin-tethering mechanism - a maleimido group covalently binding albumin Cys34 - is well characterised. Tier two is weaker: the receptor-activation and pharmacokinetic work sits largely in rat pituitary cells and short registered pharmacology studies, and a cell in a dish is not a person. Tier three is the thinnest: human data is limited to a handful of small early-phase studies whose endpoints are named here but whose results are not reproduced, so no durable human outcome can be claimed. It is not a licensed medicine, and it has not been shown to produce defined outcomes in humans. Curiosity is warranted; certainty is not.
Kovalabs supplies CJC-1295 with DAC strictly as a research chemical for laboratory research use only. It is not a medicine, supplement or veterinary product, is not for human or veterinary use, and nothing on this page constitutes a medicinal, therapeutic, efficacy, dosing or human-outcome claim. It has not been evaluated by the MHRA or any comparable regulator for safety or efficacy in humans or animals. The descriptions above are restricted to chemistry and to study designs and endpoint names. Every batch is third-party tested with a certificate of analysis. Full terms are on the research disclaimer page.
The base peptide is the same modified GRF 1-29. The DAC version adds a Drug Affinity Complex - a lysine + maleimidopropionyl group that binds covalently to serum albumin - which the literature associates with a much longer circulating persistence (days rather than minutes). The DAC form is PubChem CID 91971820 (C165H269N47O46, ~3647.2 g/mol); the no-DAC base is CID 56841945 (C152H252N44O42, 3367.9 g/mol). The roughly 279 g/mol difference is the DAC itself.
PubChem CID 91971820, CAS 446262-90-4, molecular formula C165H269N47O46, average molecular weight 3647.2 g/mol. Confirm the DAC form versus the no-DAC base by mass on the lot certificate of analysis, since both are commonly called "CJC-1295".
The DAC carries a maleimido group that reacts with a free thiol on serum albumin (Cys34), tethering the peptide to a protein that itself circulates for weeks. That shields the peptide from the rapid clearance that removes a free GHRH fragment in minutes. This is a described pharmacokinetic mechanism and a study-reported parameter, not a usable dosing fact or any statement of effect.
They act on different receptors. CJC-1295 is a GHRH analogue at the GHRH receptor; ipamorelin is a ghrelin-mimetic growth-hormone secretagogue at the GHS-R1a (ghrelin) receptor. Both sit in the somatotropic axis but engage distinct receptors. This is a receptor-pharmacology distinction only, not a combination or recommendation for any use.
As bench handling of a research reagent only. The lyophilised powder is stored sealed, desiccated, cold and out of light (frozen for long-term storage), and reconstituted in an appropriate aqueous laboratory solvent with gentle swirling, then aliquoted to avoid freeze-thaw cycles. See the reconstitution guide. None of this is a preparation method for any use in humans or animals.
No. It is supplied as a research chemical for laboratory use only, is not approved as a medicine by the MHRA or any comparable regulator, is not for human or veterinary use, and nothing on this page is a medicinal, therapeutic or efficacy claim. See the research disclaimer for full terms.
The publication titles below are the original authors' own titles, reproduced so each citation can be verified against PubMed and the cited DOI. They are not statements, conclusions or claims by Kovalabs, and the body of this page describes each study by its design and endpoint name only.